Selected research
Industry Research
Metastatic Ovarian Cancer Drug Industry Research Report 2026
Market perspective
The global Metastatic Ovarian Cancer Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Metastatic Ovarian Cancer Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Metastatic Ovarian Cancer Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Metastatic Ovarian Cancer Drug include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc. and Sumitomo Dainippon Pharma Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Metastatic Ovarian Cancer Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Metastatic Ovarian Cancer Drug Market by Company
Adgero Biopharmaceuticals Inc
Cellceutix Corporation
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Eisai Co., Ltd.
Metastatic Ovarian Cancer Drug Segment by Type
E-749
Crizotinib
LV-305
G-305
CMB-305
Others
Metastatic Ovarian Cancer Drug Segment by Application
Clinic
Hospital
Others
Metastatic Ovarian Cancer Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Ovarian Cancer Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metastatic Ovarian Cancer Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Ovarian Cancer Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Metastatic Ovarian Cancer Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Metastatic Ovarian Cancer Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Metastatic Ovarian Cancer Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- E-749
- Crizotinib
- LV-305
- G-305
- CMB-305
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Adgero Biopharmaceuticals Inc
- Cellceutix Corporation
- F. Hoffmann-La Roche Ltd.
- Immune Design Corp.
- Millennium Pharmaceuticals Inc
- MolMed S.p.A.
- Natco Pharma Limited
- Northwest Biotherapeutics, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- VG Life Sciences, Inc.
- Pfizer Inc.
- Richter Gedeon Nyrt.
- Eisai Co., Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Metastatic Ovarian Cancer Drug Market Size (2021-2032)
- 2.2.2 Global Metastatic Ovarian Cancer Drug Sales (2021-2032)
- 2.2.3 Global Metastatic Ovarian Cancer Drug Market Average Price (2021-2032)
- 2.3 Metastatic Ovarian Cancer Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 E-749
- 2.3.3 Crizotinib
- 2.3.4 LV-305
- 2.3.5 G-305
- 2.3.6 CMB-305
- 2.3.7 Others
- 2.4 Metastatic Ovarian Cancer Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Metastatic Ovarian Cancer Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Metastatic Ovarian Cancer Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Metastatic Ovarian Cancer Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Metastatic Ovarian Cancer Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Metastatic Ovarian Cancer Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Metastatic Ovarian Cancer Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Metastatic Ovarian Cancer Drug, Product Type & Application
- 3.8 Global Manufacturers of Metastatic Ovarian Cancer Drug, Established Date
- 3.9 Global Metastatic Ovarian Cancer Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Adgero Biopharmaceuticals Inc
- 4.1.1 Adgero Biopharmaceuticals Inc Company Information
- 4.1.2 Adgero Biopharmaceuticals Inc Business Overview
- 4.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
- 4.1.5 Adgero Biopharmaceuticals Inc Recent Developments
- 4.2 Cellceutix Corporation
- 4.2.1 Cellceutix Corporation Company Information
- 4.2.2 Cellceutix Corporation Business Overview
- 4.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio
- 4.2.5 Cellceutix Corporation Recent Developments
- 4.3 F. Hoffmann-La Roche Ltd.
- 4.3.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.3.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.3.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.4 Immune Design Corp.
- 4.4.1 Immune Design Corp. Company Information
- 4.4.2 Immune Design Corp. Business Overview
- 4.4.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.4.5 Immune Design Corp. Recent Developments
- 4.5 Millennium Pharmaceuticals Inc
- 4.5.1 Millennium Pharmaceuticals Inc Company Information
- 4.5.2 Millennium Pharmaceuticals Inc Business Overview
- 4.5.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
- 4.5.5 Millennium Pharmaceuticals Inc Recent Developments
- 4.6 MolMed S.p.A.
- 4.6.1 MolMed S.p.A. Company Information
- 4.6.2 MolMed S.p.A. Business Overview
- 4.6.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.6.5 MolMed S.p.A. Recent Developments
- 4.7 Natco Pharma Limited
- 4.7.1 Natco Pharma Limited Company Information
- 4.7.2 Natco Pharma Limited Business Overview
- 4.7.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio
- 4.7.5 Natco Pharma Limited Recent Developments
- 4.8 Northwest Biotherapeutics, Inc.
- 4.8.1 Northwest Biotherapeutics, Inc. Company Information
- 4.8.2 Northwest Biotherapeutics, Inc. Business Overview
- 4.8.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.8.5 Northwest Biotherapeutics, Inc. Recent Developments
- 4.9 Sumitomo Dainippon Pharma Co., Ltd.
- 4.9.1 Sumitomo Dainippon Pharma Co., Ltd. Company Information
- 4.9.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
- 4.9.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.9.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
- 4.10 VG Life Sciences, Inc.
- 4.10.1 VG Life Sciences, Inc. Company Information
- 4.10.2 VG Life Sciences, Inc. Business Overview
- 4.10.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.10.5 VG Life Sciences, Inc. Recent Developments
- 4.11 Pfizer Inc.
- 4.11.1 Pfizer Inc. Company Information
- 4.11.2 Pfizer Inc. Business Overview
- 4.11.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.11.5 Pfizer Inc. Recent Developments
- 4.12 Richter Gedeon Nyrt.
- 4.12.1 Richter Gedeon Nyrt. Company Information
- 4.12.2 Richter Gedeon Nyrt. Business Overview
- 4.12.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.12.5 Richter Gedeon Nyrt. Recent Developments
- 4.13 Eisai Co., Ltd.
- 4.13.1 Eisai Co., Ltd. Company Information
- 4.13.2 Eisai Co., Ltd. Business Overview
- 4.13.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
- 4.13.5 Eisai Co., Ltd. Recent Developments
5 Global Metastatic Ovarian Cancer Drug Market Scenario by Region
- 5.1 Global Metastatic Ovarian Cancer Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Metastatic Ovarian Cancer Drug Sales by Region: 2021-2032
- 5.2.1 Global Metastatic Ovarian Cancer Drug Sales by Region: 2021-2026
- 5.2.2 Global Metastatic Ovarian Cancer Drug Sales by Region: 2027-2032
- 5.3 Global Metastatic Ovarian Cancer Drug Revenue by Region: 2021-2032
- 5.3.1 Global Metastatic Ovarian Cancer Drug Revenue by Region: 2021-2026
- 5.3.2 Global Metastatic Ovarian Cancer Drug Revenue by Region: 2027-2032
- 5.4 North America Metastatic Ovarian Cancer Drug Market Facts & Figures by Country
- 5.4.1 North America Metastatic Ovarian Cancer Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
- 5.4.3 North America Metastatic Ovarian Cancer Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Metastatic Ovarian Cancer Drug Market Facts & Figures by Country
- 5.5.1 Europe Metastatic Ovarian Cancer Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
- 5.5.3 Europe Metastatic Ovarian Cancer Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Metastatic Ovarian Cancer Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Metastatic Ovarian Cancer Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Metastatic Ovarian Cancer Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Metastatic Ovarian Cancer Drug Market Facts & Figures by Country
- 5.7.1 South America Metastatic Ovarian Cancer Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
- 5.7.3 South America Metastatic Ovarian Cancer Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Metastatic Ovarian Cancer Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Metastatic Ovarian Cancer Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Metastatic Ovarian Cancer Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
- 6.1.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
- 6.2.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Metastatic Ovarian Cancer Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
- 7.1.1 Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
- 7.2.1 Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Metastatic Ovarian Cancer Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Metastatic Ovarian Cancer Drug Value Chain Analysis
- 8.1.1 Metastatic Ovarian Cancer Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Metastatic Ovarian Cancer Drug Production Mode & Process
- 8.2 Metastatic Ovarian Cancer Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Metastatic Ovarian Cancer Drug Distributors
- 8.2.3 Metastatic Ovarian Cancer Drug Customers
9 Global Metastatic Ovarian Cancer Drug Analyzing Market Dynamics
- 9.1 Metastatic Ovarian Cancer Drug Industry Trends
- 9.2 Metastatic Ovarian Cancer Drug Industry Drivers
- 9.3 Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges
- 9.4 Metastatic Ovarian Cancer Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst